EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 182 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 2.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $405,000 | -39.7% | 6,746 | -43.2% | 0.01% | -37.5% |
| Q3 2019 | $672,000 | -24.5% | 11,878 | -25.7% | 0.01% | -20.0% |
| Q2 2019 | $890,000 | +10.8% | 15,983 | +0.6% | 0.01% | 0.0% |
| Q1 2019 | $803,000 | +17.7% | 15,895 | -6.2% | 0.01% | +11.1% |
| Q4 2018 | $682,000 | -39.2% | 16,937 | +4.8% | 0.01% | -18.2% |
| Q3 2018 | $1,121,000 | +22.5% | 16,162 | +33.7% | 0.01% | +22.2% |
| Q2 2018 | $915,000 | +32.0% | 12,091 | -8.0% | 0.01% | +28.6% |
| Q1 2018 | $693,000 | -7.6% | 13,144 | -6.4% | 0.01% | 0.0% |
| Q4 2017 | $750,000 | +186.3% | 14,044 | +219.2% | 0.01% | +133.3% |
| Q3 2017 | $262,000 | -18.9% | 4,400 | +7.3% | 0.00% | -25.0% |
| Q2 2017 | $323,000 | -7.2% | 4,100 | -2.4% | 0.00% | -20.0% |
| Q1 2017 | $348,000 | +7.1% | 4,200 | +2.4% | 0.01% | 0.0% |
| Q4 2016 | $325,000 | +13.2% | 4,100 | 0.0% | 0.01% | +25.0% |
| Q3 2016 | $287,000 | – | 4,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
| Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
| Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
| U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
| Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
| CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
| ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
| Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
| GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |